GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (LTS:0HFQ) » Definitions » Debt-to-Revenue

AnaptysBio (LTS:0HFQ) Debt-to-Revenue : 0.14 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is AnaptysBio Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

AnaptysBio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.89 Mil. AnaptysBio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $14.61 Mil. AnaptysBio's annualized Revenue for the quarter that ended in Sep. 2024 was $120.07 Mil. AnaptysBio's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.14.


AnaptysBio Debt-to-Revenue Historical Data

The historical data trend for AnaptysBio's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio Debt-to-Revenue Chart

AnaptysBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.01 0.33 1.89 1.04

AnaptysBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 0.50 0.61 0.39 0.14

Competitive Comparison of AnaptysBio's Debt-to-Revenue

For the Biotechnology subindustry, AnaptysBio's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnaptysBio's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Debt-to-Revenue falls into.



AnaptysBio Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

AnaptysBio's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.777 + 16.037) / 17.157
=1.04

AnaptysBio's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.887 + 14.607) / 120.068
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


AnaptysBio Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of AnaptysBio's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AnaptysBio Business Description

Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

AnaptysBio Headlines

No Headlines